Skip to main content
. 2015 Nov 17;182(11):952–960. doi: 10.1093/aje/kwv181

Table 1.

Percentage of Person-Time Retained in Care for HIV-Positive Patients as Defined by Both Primary Care Encounters and Laboratory Measures, According to Demographic, Clinical, and Geographic Characteristics, NA-ACCORD, 2000–2010a

Factor No. of Patients %b % of Person-Time Retainedc
Agreement Between RLB and REB
REB RLB κ %
Total 83,041 100 71 67 0.59 80
Age, years
 <40 35,713 43 62 63 0.64 83
 40–49 29,542 36 70 67 0.61 83
 50–59 13,863 17 77 68 0.53 81
 ≥60 3,923 5 84 70 0.39 78
Sex
 Male 67,951 82 71 66 0.57 80
 Female 15,090 18 69 69 0.57 80
Race/ethnicity
 Non-Hispanic white 33,207 40 72 69 0.56 82
 Non-Hispanic black 34,175 41 69 62 0.60 82
 Hispanic 9,510 11 72 73 0.64 86
 Other/unknown 6,149 7 70 67 0.59 82
Primary HIV risk factor
 Men who have sex with men 30,589 37 69 74 0.63 85
 Injection drug user 14,329 17 69 58 0.58 80
 Heterosexual contact 18,908 23 68 71 0.65 85
 Other/unknown 19,215 23 76 59 0.49 77
CD4-positive T-lymphocyte count, cells/mm3 d
 <200 19,322 29 70 69 0.64 85
 200–349 14,718 22 73 74 0.63 86
 350–499 12,940 20 74 75 0.61 85
 ≥500 19,061 29 75 76 0.59 85
HIV-1 RNA level, copies/mLd
 <200 16,972 27 81 83 0.52 86
 ≥200 45,205 73 69 68 0.63 84
Receipt of ART for ≥6 months/yeare
 No ART 46,449 56 50 42 0.57 79
 ART 36,592 44 83 82 0.46 84
Country of care
 United States 79,236 95 70 66 0.58 82
 Canada 3,805 5 74 75 0.66 87

Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; HIV-1, HIV type 1; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design.

a Encounter-based retention (REB) was defined as ≥2 primary care encounters in a calendar year, ≥90 days apart. Laboratory-based retention (RLB) was defined similarly, using the dates of CD4-positive cell counts or HIV-1 RNA measurements.

b Percentages may not sum to 100 because of rounding.

c The percentage of person-time retained in care during the study according to the encounter-based measure (REB) (i.e., the percentage of years spent “in care” between cohort entry and the final encounter) differed from the percentage of person-time retained according to the laboratory-based measure (RLB) within every stratum (χ2 test: P < 0.01).

d Data on CD4-positive cell count (n = 66,041) and HIV-1 RNA level (n = 62,177) at cohort entry were not available for all participants.

e Receipt of ART (≥3 agents from ≥2 classes or a triple nucleoside/nucleotide reverse transcriptase inhibitor regimen containing abacavir or tenofovir) during the year of cohort entry.